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Background: Surfactant Protein D (SP-D) is an important marker in chronic obstructive pulmonary disease (COPD).
Serum SP-D levels increase while lung production of SP-D decreases in COPD. SP-D is a specific biomarker for
monitoring COPD, assessment of exacerbation frequency and arrangement of treatment modalities. In the present
study, we aimed to investigate the correlation between serum and induced sputum SP-D levels with severity and
acute exacerbations of COPD.
Method: 20 healthy subjects, older than 40 years, with at least 10 pack/years smoking history (group 1), 20 stage I-II
COPD patients (group 2) , and 20 stage III-IV COPD patients (group 3) were enrolled in the study. All subjects
performed pulmonary function tests. Venous blood samples were taken to determine complete blood count,
C-reactive protein(CRP) and serum SP-D levels. Induced sputum samples were obtained to determine SP-D level.
COPD patients were followed up for acute exacerbations for 6 months.
Results: Serum SP-D levels of group 3 were the highest and induced sputum SP-D levels of group 2 were the
lowest among the three groups. SP-D levels of induced sputum decreased in patients with increasing number of
cigarette pack/years (p = 0.03, r = −0.115), whereas serum SP-D levels increased in these patients (p = 0.0001, r = 0.6 ).
Induced sputum SP-D levels in COPD patients receiving inhaled corticosteroid treatment were significantly higher
than in patients who were not receiving inhaler corticosteroid treatment (p = 0.005). An inverse correlation between
serum SP-D levels and FEV1 (%) was found and there was a positive correlation between the serum SP-D levels and
exacerbations frequency in 6-month follow up period (p = 0.049 ,r = −0.252; p = 0.0001, r = 0.598 respectively).
Conclusion: Our study demonstrates the adverse effects of smoking on local SP-D levels since low levels of
induced sputum SP-D were found in the group of current smokers, who were not receiving inhaled corticosteroid
treatment. Relationship between serum SP-D and COPD exacerbations frequency suggests that serum SP-D level
may be used as a lung-specific biomarker during the follow up and progression of COPD.
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Chronic obstructive pulmonary disease (COPD) is a
complex chronic inflammatory disease that involves the
activity of various inflammatory cells and mediators [1].
Both local and systemic inflammatory reactions are ob-
served in COPD. There are ongoing researches trying to
find out different markers in COPD course. For instance,* Correspondence: sevincsarinc@gmail.com
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distribution, and reproduction in any mediumsurfactant protein D (SP-D) is one of the most fre-
quently studied markers contributing to immune and
inflammatory regulation within lungs. SP-D is a 43kDa
member of the collectin family that is produced from
collagenous glycoprotein in type II pneumocytecells. SP-
D is a protein responsible for homeostasis which has an
important protective role in the immune system against
inhaled microorganisms and allergens. It plays a part in
protection against viral, bacterial, and fungal infections,
as well as apoptotic cells [2]. Serum SP-D concentration
exhibits an increase together with the decrease inCentral Ltd. This is an Open Access article distributed under the terms of the
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SP-D level and FEV1 display a negative correlation in
COPD [3]. Higher serum SP-D levels have been found
[3] in advanced COPD cases with worsening health and
aggravating shortness of breath. SP-D is thought to play
a role in the pathogenesis and progression of COPD [4].
SP-D level declines as the disease progresses. There are
also some studies indicating the increase of BAL SP-D
level using inhaled corticosteroids. The association be-
tween decreased SP-D level in lungs and smoking has
also been demonstrated in previous studies [5,6]. There-
fore, SP-D is a promising biomarker that might help to
determine the health status of patients with lung dis-
eases, particularly with respect to progression of dyspnea
and decreasing pulmonary functions.
SP-D of serum and BAL or induced sputum may be
used as a lung specific biomarker in the assessment of
COPD progression and management. The number of
studies investigating the relationship between local and
systemic SP-D levels with COPD is not as high as it
should be. Therefore, in the present study we aim to
investigate the relationships between COPD severity and
acute exacerbations frequency with serum and induced
sputum SP-D levels.
Methods
This study was approved by the Research Committee
of the Medical Faculty and Health Sciences, Baskent
University (project# KA09/277) and supported by the
Research Fund of Baskent University. Written in-
formed consent was obtained from each participating
patient and control subjects prior to the study.
Our study sample comprised of 60 subjects in total: a
control group including 20 individuals (16 smokers and
4 ex-smokers) above 40 years of age (mean age: 44.85 ±
5.80 years) and with a history of at least 10 pack year
cigarette consumption (mean cigarette pack year: 23 ±
13 pack year) (Group 1), 20 mild and moderate COPD
patients (Group 2), and 20 severe and very severe COPD
patients (Group 3) based on GOLD classification [7].
The patients below 40 years of age and those with a
history of COPD exacerbation/infection within the last 4
weeks, cardiac disease, chronic liver and kidney failure,
asthma, malignancy, hypertension, diabetes mellitus, and
any additional medical disorders were excluded from the
study.
In our study all patients and control subjects performed
pulmonary function tests (PFT). Furthermore, venous
blood sample was collected from each participant for evalu-
ating complete blood count (CBC), C-reactive protein
(CRP), and serum SP-D level. Induced sputum specimen
was obtained and also tested for induced sputum SP-D
level. COPD patients were followed for 6 months to deter-
mine exacerbation frequency. Acute exacerbation of COPDwas defined as a sustained (lasting 48 hours or more) wors-
ening of dyspnea, cough or sputum production leading to
an increase in the use of maintenance medications and/or
supplementation with additional medications [7,8]. The
data concerning the exacerbation frequency were collected
via hospital visits and telephone calls.
Measurement of biochemical parameters
Venous blood sample was obtained from each patient. 3
ml venous peripheral blood specimen was put into a
tube with K3-EDTA for CBC and 5 ml venous peripheral
blood specimen was put into an additive-free tube for
analysis of CRP and SP-D levels. Serum samples were
prepared by collecting blood in a vacuum tube and
allowing it to clot for 30 minutes at room temperature.
About 1mL of serum was obtained after centrifugation
at 1100g for 10 minutes and stored in small aliquots
at −80°C until analysis. SP-D level was studied by
ELISA immunoassay method. Serum CRP level was
measured by an ultrasensitive latex-enhanced immuno-
assay method, using CRP Ultra reagent (Sentinel Diagnos-
tics, Milan, Italy) in Abbott Architect C8000 Analyzer
according to the manufacturer’s specifications. The detec-
tion limit was 0.2 mg/L. The inter- and intra-assay vari-
ability were 8.22% and 4.84%, respectively. CBC was
carried out with Abbott Cell-Dyne® 3700 System device
(Abbott Diagnostics, Santa Clara, CA, USA).
Pulmonary function test
Pulmonary function test was performed with a clinical
spirometer (SensorMedicsVmax spectra 229, Bilthoven,
The Netherlands) according to the ERS standards [9].
We carried out forced vital capacity (FVC) and forced
expiratory volume (FEV1) measurements, and calculated
the FEV1/FVC ratio. Total lung capacity (TLC), residual
volume (RV), functional residual capacity (FRC), and
vital capacity (VC) were measured by the multiple nitro-
gen washout method. Twenty healthy individuals having
normal PFTs and 40 patients diagnosed as mild, moder-
ate, severe, and very severe COPD based on the current
Global Initiative for Chronic Obstructive Lung Disease
(GOLD) guidelines using postbroncodilatator FEV1
values (post bronchodilator values were obtained after
400 mcg salbutamol inhalation), were enrolled in the
study [7].
Induced sputum analysis
The patients were informed about the process and FEV1
values were measured before the bronchodilatation.
Then, 10 minutes after inhaling 400 μg salbutamol, post-
bronchodilatator FEV1 values were measured. Induction
was started with 3% NaCl in patients with FEV1 value
>1 L or >60%. This was continued for a period up to
20 minutes by incremental doses applied with
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measured after each induction. If 20% or more decrease
in FEV1 values was detected, process was terminated.
The induction started using 0.9% NaCL with nebulizer
in patients with a FEV1 value <1 L or <60%. The induc-
tion was carried out for 30 seconds, 1 minute, and 5 mi-
nutes. At the end of these time intervals, FEV1 value was
re-measured and induction was discontinued if there
was a decrease of 20% or more. Induction with higher
concentration was not applied to patients when ad-
equate material could be obtained at this concentration.
If the patient failed to produce sputum and/or adequate
sputum at these concentrations, induction was applied
using 3% NaCl with nebulizer and it was carried out for
30 seconds, 1 minute, and 2 minutes. At the end of these
time intervals, FEV1 value was measured again and in-
duction was discontinued if there was a decrease of 20%
or more. Induction with a higher concentration was not
applied to patients when adequate material could be
obtained at this concentration. If the patient failed to
produce sputum and/or adequate sputum at this con-
centration, induction was applied with 4.5% NaCl and it
was carried out for 30 seconds, 1 minute, 2 minutes, and
4 minutes. At the end of these times, FEV1 value was
measured again and induction was discontinued if there
was a decrease of 20% or more. Following each induc-
tion, participants were asked to rinse their mouth with
water and produce sputum by cough.
The processing of induced sputum
The induced sputum was immediately analyzed following
the acquirement. Firstly, the specimen was weighed. Spu-
tum was treated with Sputalysin (0.1% DTT) by mixing the
agent in a 1:1 ratio with the specimen. The mixture was
vortexed for 15 minutes at room temperature and there-
after it was filtered through a 48μm-thick nylon filter. The
resulting filtrate was weighed. The cell viability of the
filtrate was evaluated by Trypan blue and total cell count
(TCC) was calculated on a Thoma slide. TCC was calcu-
lated by following the formula: Average number of cells in
one large square x dilution factor* x 104 (*dilution factor is
2x2 = 4 (1:1 dilution with Sputalysin and 1:1 dilution with
trypan blue)). The filtrate (790μg) was centrifuged at 4°C
for 10 minutes. The resultant supernatant was sepa-
rated and put into Falcon tubes. These tubes were
stored at −20°C.
Induced sputum and serum SP-D level determination
Surfactant protein D concentration in serum and in-
duced sputum samples was determined by a sandwich
enzyme-linked immunosorbent assay (ELISA) system
(SP-D; Biovendor, Brno, Czech Republic). For SP-D, the
inter- and intraassay CV were 3.7% and 2.3%, respec-
tively, and the sensitivity was 0.01 ng/ml.Statistical analysis
The statistical analyses of our study were performed using
SPSS statistical software version 15.0. The variables were
investigated using visual (histograms, probability plots) and
analytical methods (Kolmogorov-Simirnov test) to deter-
mine the normality of distributions. The results were
expressed as mean ± standard deviation and median value.
For continuous variables without normal distribution
Mann–Whitney U test was used for the comparison of the
two groups (patients receiving inhaler steroids or not re-
ceiving inhaler steroids), whereas Kruskal-Wallis test for
the comparison of parameters between 3 groups. T- test
was used for the comparison of parameters with normal
distribution between 2 groups and ANOVA together with
Bonferroni correction was used for the comparison of con-
tinuous parameters with normal distribution among the
three groups. The parameters affecting 6 month exacerba-
tion frequency, induced sputum and serum surfactant pro-
tein D levels were investigated using Spearman correlation
analysis. Multiple linear regression models were used to
identify independent predictors of 6 month exacerbation
frequency, serum and induced sputum surfactant protein
D levels. The model fit was assessed using appropriate
residual and goodness of fit statistics. A 5% type-I error
level was used to infer statistical significance.Results
The demographic characteristics, PFT parameters and
complete blood count results of our study groups are
reported in Table 1. CRP levels of group I were the low-
est among study groups (p = 0.03).
Smoking status (active, ex-smoker) of the groups was
also evaluated. 80% of the healthy individuals (n = 16) in
Group 1, 50% of patients (n = 10) in Group 2, and 10% of
patients (n = 2) in Group 3 were active smokers. The
amount of cigarette consumption (pack/years) was 20
pack/years in Group 1, 45 pack/years in Group 2, and 45
pack/years in Group 3. When we asked the ongoing
bronchodilatator and/or oxygen therapy of COPD patients,
24 patients were found to be on inhaled corticosteroid
therapy and 12 patients on nasal oxygen therapy due to
type I respiratory failure (Table 2). Mean duration of in-
haled steroid treatment was 5.31 ± 3.81 years.
The serum and sputum SP-D values of subjects in all
three groups were compared (Table 3). Serum SP-D levels
of Group 3 were the highest and serum SP-D levels of
Group 2 were higher than Group 1. However, there was no
statistically significant difference among the three groups in
terms of serum SP-D level (p = 0.099). In addition, we did
not find statistically significant difference among the three
groups in terms of induced sputum SP-D levels (p = 0.836).
Although, induced sputum SP-D levels in Group 2 were
the lowest, they did not achieve to the significance level.
Table 1 Demographic characteristics and respiratory function test results of the study population
Group 1 (control subjects) Group 2 (stage 1 and
2 COPD patients)
Group 3 (stage 3 and
4 COPD patients) P
(n = 20) (n = 20) (n = 20)
Mean Age (year) 44.85 ± 5.80 60.35 ± 9.40 63.70 ± 8.60 p = 0.001
Gender (F/M) 8/12 0/20 3/17 p = 0.004
Mean BMI (kg/m2) 33.36 ± 5.70 32.8 ± 6.70 29.6 ± 5.90 p = 0.148
Smoking status
Active smokers 16 (80%) 10 (50%) 2 (10%) p = 0.001
Ex-smokers 4 (20%) 10 (50%) 18 (90%)
Cigarette pack years 23 ± 13 (20) 51 ± 28 (45) 51 ± 33(45) p = 0.001
Inhaled steroid use 0 6 18 p = 0.001
Mean FVC (%) 131.5 ± 15.1 101.7 ± 19 76.7 ± 16.8 p = 0.001
Mean FEV1 (%) 123 ± 14 75.7 ± 16.4 39.7 ± 7.24 p = 0.001
Mean FEV1/FVC (%) 78.9 ± 4.8 59.75 ± 10.8 43.3 ± 11.3 p = 0.001
Mean FEF25-75 (%) 94.5 ± 23.4 33.5 ± 18.6 12.5 ± 4.54 p = 0.001
Mean VC (%) 130 ± 16.9 94.5 ± 19 80.8 ± 19 p = 0.001
Mean RV (%) 120 ± 29 156 ± 37 150 ± 77 p = 0.001
Mean SpO2 (%) 96.6 ± 1.1 94 ± 1.9 92.1 ± 2.1 p = 0.001
Mean CRP level (mg/L) 2.52 ± 2.4 8.3 ± 10 8.1 ± 9.49 p = 0.014
Mean Hb (g/dl) 14.21 ± 1.55 14.7 ± 1.43 14.6 ± 14 p = 0.282
Mean WBC (/μL) 7.449 ± 1.704 7.291 ± 1.084 8.402 ± 1.694 p = 0.102
Mean PMNL (/μL) 4.272 ± 1.166 4.310 ± 956 5.519 ± 1.205 p = 0.003
The results are expressed as mean ± standard deviation.
BMI Body mass index, CRP C-reactive protein, FEV1 forced expiratory volume, FRC functional residual capacity, FVC forced vital capacity, Hb hemoglobin,
PMNL polymorphonucleer leukocyte, RV residual volume, TLC total lung capacity, VC vital capacity, WBC white blood cell count.
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ships between cigarette consumption (pack year) and
serum/sputum SP-D levels. While sputum SP-D and
cigarette consumption demonstrated a negative corre-
lation (p = 0.03, r = −0.115), serum SP-D and cigarette
consumption showed a positive correlation (p = 0.0001,
r = 0.6 ).No significant difference was observed between
genders in terms of serum/sputum SP-D levels and cell
viability.Table 2 Treatment modalities of COPD patients
Group 2 (stage 1 and 2 COP
(n = 20)
Short acting β2 agonist 6
Long acting β2 agonist 12
Long acting anticholinergic 7
Inhaler steroid 6
N-acetyl systein 2
Long term oxygen therapy 2
Pulmoner rehabilitation 0Serum SP-D levels were significantly correlated with
FEV1 (%) (p = 0.049; r = −0.252). However no signifi-
cant correlation was found between FEV1 (%) and in-
duced sputum SP-D levels (p = 0.92, r = −0.013).
Induced sputum and serum SP-D levels were significantly
different between patients with and without inhaled cor-
ticosteroid therapy (p = 0.005 and 0.038 respectively). The
COPD patients receiving inhaled corticosteroid therapy had









Table 3 Comparison of SP-D levels and cell viability among the study groups
Group 1 (control subjects) Group 2 (stage 1 and 2 COPD patients) Group 3 (stage 3 and 4 COPD patients)
p
(n = 20) (n = 20) (n = 20)
Serum SP-D (ng/ml) 86.2 ± 49 108.9 ± 65 129 ± 71 p = 0.10
Sputum SP-D (ng/ml) 33.1 ± 34 28 ± 15.2 30.42 ± 12.8 p = 0.83
Viability % 73.5 ± 12.1 79.8 ± 11.2 80.1 ± 19 p = 0.86
The results were expressed as mean ± standard deviation.
COPD Chronic obstructive pulmonary disease, SP-D surfactant protein D.
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inhaled steroid treatment was significantly correlated with
induced sputum SP-D levels whereas no significant corre-
lation was evidenced with serum SP-D levels (p = 0.0001,
r = 0.800; p = 0.59, r = 0.104 respectively).
We also evaluated the relationships between serum/spu-
tum SP-D levels and 6-month exacerbation frequency in
COPD patients of Groups 2 and 3. There was no signifi-
cant correlation between sputum SP-D levels and 6-month
exacerbation frequency (p = 0.051; r = 0.342). However,
patients with increased serum SP-D levels had signifi-
cantly higher 6-month exacerbation frequency (p = 0.0001;
r = 0.59). The other parameters such as BMI, cigarette
pack years, FEV1(%) and number of years on inhaled ste-
roid treatment were not correlated with 6-month exacer-
bation frequency (p = 0.39, r = 0.152; p = 0.117 r =−0.278;
p = 0.177, r =−0.241; p = 0.137, r = 0.294 respectively).
Multiple linear regression analyses were conducted
after adjusting for age, cigarette pack years, BMI, FEV1
(L), FEV1(%), number of years on inhaled steroid treat-
ment, serum and induced sputum SP-D levels; only
serum SP-D levels were found to be significantly associ-
ated with acute exacerbation frequency (p =0.0001).
Sputum surfactant protein D level was found to be sig-
nificantly associated with number of years on inhaled
steroid treatment (p = 0.0001). Serum surfactant protein
D level was significantly related with 6 month exacerba-
tion frequency (p = 0.0001) (Table 5).
Discussion
In this study, we investigated the relationships between
local and systemic SP-D levels, and course of COPD by
evaluating serum and induced sputum SP-D levels. In
the literature review, no study including both induced
sputum and serum SP-D measurement in COPD pa-
tients has been found according to our knowledge.
Induced sputum analysis has been recently recognized
as a valuable method for revealing the pathogenesis ofTable 4 Comparison of patients with and without inhaled cor
COPD patients receiving inhaled steroid (n = 24
Serum SP-D (ng/ml) 132 ± 71
Sputum SP-D (ng/ml) 35.5 ± 14
The results were expressed as mean ± standard deviation.
COPD Chronic obstructive pulmonary disease, SP-D surfactant protein D.inflammatory airway diseases such as COPD and asthma,
and monitoring the activity and treatment response in
these pathologies [10-13]. Currently, induced sputum is
recognized to reflect lower respiratory tract inflammation
[10,13]. Therefore, we preferred to use induced sputum
specimens, also known as cost-effective diagnostic tool,
in evaluating the courses of local and systemic inflamma-
tion in COPD.
Previous studies have demonstrated a positive corre-
lation between cigarette consumption (pack year) and
serum SP-D levels. Serum SP-D concentrations have
been found to be higher in current smokers than in ex-
smokers [2,14]. In our study, among COPD patients,
there was a negative correlation between induced sputum
SP-D levels and cigarette consumption (pack year),
whereas serum SP-D levels and cigarette consumption
(pack year) showed a positive correlation.
The comparison of induced sputum SP-D levels
among three groups revealed no statistically significant
difference. Sputum SP-D concentrations of Group 2
were lowest among study groups. Furthermore, 50% of
patients in Group 2 were currently active smokers. In-
haled corticosteroid treatment was more common in
Group 3 due to increased airway obstruction level and
exacerbation frequency of severe and very severe COPD
patients. Sputum SP-D levels were significantly different
between patients with and without inhaled corticosteroid
therapy in the present study. Moreover, significant cor-
relation was also found between number of years on in-
haled corticosteroid treatment and induced sputum SP-
D levels in linear regression analysis. These results also
support the fact that the use of inhaled corticosteroids
indirectly contributes to the local SP-D levels in a posi-
tive way [15]. Ishikawa et al. found increased induced
sputum SP-D levels in 28 COPD patients compared to
subjects with prolonged cough [16]. They included pa-
tients with mild, moderate and severe COPD patients,
and subjects with prolonged cough as control group andticosteroid therapy
) COPD patients not receiving inhaled steroid (n = 16) p
99 ± 59 0.038
20 ± 7.8 0.005
Table 5 Multiple linear regression models
Multiple linear regression model for six month exacerbation frequency by serum and induced sputum SP-D levels
Coefficient B Standard error t p
Constant −0.37 0.32 −1.15 0.25
Serum SP-D levels 0.008 0.002 4.22 0.0001
Sputum SP-D levels 0.011 0.009 1.18 0.247
Multiple linear regression model for induced sputum SP-D levels by six month exacerbation frequency and number of years on inhaled steroid
treatment.
Coefficient B Standard Error t p
Constant 16.948 3.78 4.4 0.0001
Six month exacerbation frequency 1.38 2.14 0.64 0.525
Number of years on inhaled steroid treatment 2.848 0.53 5.37 0.0001
Multiple linear regression model for serum SP-D levels by age, FEV1 (%) and six month exacerbation frequency
Coefficient B Standard error t p
Constant 17.660 70.64 0.25 0.80
Age 1.461 1.08 1.35 0.187
FEV1(%) −0.61 0.45 −1.36 0.182
Six month exacerbation frequency 42.598 9.85 4.32 0.0001
FEV1 forced expiratory volume, SP-D surfactant protein D.
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rent results might be due to the fact that study popula-
tions and medications in the study by Ishiwaka et al.
were different from those in present study.
In COPD patients, serum SP-D levels and FEV1 show
a negative correlation, whereas lung SP-D levels and
FEV1 exhibit a slightly positive correlation [3]. In the
present study, serum SP-D levels were negatively corre-
lated with FEV1(%) and group 3 had the highest serum
SP-D levels among study groups. Group 2 had higher
serum SP-D levels than Group 1, although, these diffe-
rences did not reach to significance level. We believe
that low number of patients in all groups was a limita-
tion for the statistical comparison.
We had a higher number of males than females in study
groups (F/M:11/49). In a recent study COPD rate was
reported as four times higher in males than females in our
country and total smoking, biomass, and occupational ex-
posure were also found to be overwhelmingly higher in
males than females (16.1% and 3.9% respectively) [17].
Therefore, these results could be attributed to a higher
incidence of COPD in males as higher incidence of smo-
king and environmental/occupational exposure in our
country.
Acute exacerbations that are observed during the
course of the COPD are significant causes of morbidity
and mortality [18,19]. Some COPD patients exhibit a
higher acute exacerbation frequency mostly due to the
infections of tracheobronchial tree. Some studies dem-
onstrate that increased airway inflammation incidence
may have a role in the elevated acute exacerbation fre-
quency [18]. Our patients were followed up for 6 monthsfor acute exacerbations. In 20 (50%) of our COPD patients
in group 2 or 3, the acute exacerbation frequency varied
between 1 and 3 within a 6 month follow-up period. 85%
of 20 patients with a history of exacerbation were moder-
ate, severe, and very severe COPD cases. This finding is
consistent with the fact that raised airway inflammation
increases the frequency and number of acute
exacerbations.
In advanced COPD patients especially with frequent
acute exacerbations, markers of systemic inflammation
such as cytokines, chemokines, and acute phase proteins
have been used [18-20]. SP-D, has also been proposed to
be a lung-specific biomarker in COPD cases [21]. Ele-
vated serum SP-D levels can show the poor health status
of COPD patients within a 3 month period [3]. Also
Shakoori TA et al. demonstrated in COPD patients
higher levels of serum SP-D levels during acute exacer-
bation than during stable period [22]. In our study, we
determined a significant relationship between serum SP-D
level and number of acute exacerbations within a 6 month
period. In addition, we strengthen our hypothesis in linear
regression analysis and found that the only significant
determinant of 6 month exacerbation frequency was
serum SP-D. These findings also suggest that SP-D level
may be a lung-specific biomarker that can be used for
monitoring COPD and its progression.
Limitations
The limitations of our study were the unequal number
of female and male patients, the absence of a non-
smoker healthy control group, and the failure to con-
vince higher number of patients to participate in the
Akinci Ozyurek et al. Multidisciplinary Respiratory Medicine 2013, 8:36 Page 7 of 7
http://www.mrmjournal.com/content/8/1/36study. Further studies with larger sample sizes are
needed to confirm and explore the findings of the
present study.
Conclusions
In conclusion, we believe that our preliminary study dem-
onstrates a significant relationship between serum SP-D
and COPD exacerbation frequency which suggests that
serum SP-D level may be used as a lung-specific bio-
marker during the follow-up and progression of COPD.
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